A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis (clinicaltrials.gov) - Oct 28, 2026 - P2 | N=18 | Terminated | Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | N=403 ➔ 18 | Trial completion date: Dec 2027 ➔ Aug 2026 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2027 ➔ Aug 2026; Sponsor Decision
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13
|